NexMed Appoints Dr. Stephen B. Howell, World Renowned Key Opinion Leader in Oncology as Chairman of Its Scientific Advisory B...
27 Aprile 2010 - 10:40PM
Business Wire
NexMed, Inc. (Nasdaq: NEXM), a specialty CRO and a developer of
products based on the NexACT® technology, today announced the
appointment of Stephen B. Howell, M.D., as Chairman of its
Scientific Advisory Board.
Commenting on today’s news, Dr. Bassam Damaj, Chief Executive
Officer of NexMed, noted, “We are very pleased to welcome Steve as
Chairman of our Scientific Advisory Board. He is recognized as a
world-class, key opinion leader in oncology and his expertise will
be especially valuable as we continue the development of our cancer
therapies.”
Dr. Howell currently serves as a medical oncologist and
Professor of Medicine at the University of California, San Diego.
He also serves as Associate Director for Clinical Research and
Director of the Cancer Therapeutics Training Program at the Moores
Comprehensive Cancer Center at the University of California, San
Diego, and runs the Clayton Foundation Drug Resistance Laboratory
at the Cancer Center. During his career, Dr. Howell has co-founded
three pharmaceutical companies, including DepoTech (1989), Beacon
Laboratories (1995), and Targa Pharmaceuticals (2003), serving as
Medical Director of each.
Dr. Howell holds a number of patents for his innovative work in
chemotherapeutics, drug-delivery systems, and diagnostic assays and
is the recipient of numerous awards, including the Milken Family
Medical Foundation Award for Outstanding Work in the Field of
Cancer Research, a presidential citation from the American Head and
Neck Society, and a Fogarty Senior International Fellowship. He is
currently one of the main organizers of the American Association of
Cancer Research.
Dr. Howell is a graduate of Harvard Medical School and is board
certified in internal medicine and medical oncology. He completed
his internship, residency, and medical oncology training at the
Massachusetts General Hospital, the University of California, San
Francisco, and the Dana Farber Cancer Institute, respectively. He
completed his research training at the National Institutes of
Health.
About NexMed
NexMed is the largest specialty CRO based in San Diego, CA and
is one of the industry's most experienced CROs for in vitro and in
vivo pharmacology services and research models. The Company's goal
is to generate revenues from the growth of its Discovery
Pre-clinical CRO business, while aggressively seeking to monetize
its proprietary NexACT drug delivery technology through
out-licensing agreements with pharmaceutical and biotechnology
companies, worldwide. At the same time, NexMed has embarked on a
partnering program to pair the NexACT delivery technology with
drugs and drug candidates marketed and being developed by others,
including NexACT-based treatments for onychomycosis, psoriasis,
sexual dysfunction and cancer. For further information, go to
www.nexmed.com and www.bio-quant.com.
Grafico Azioni Nexmed (MM) (NASDAQ:NEXM)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Nexmed (MM) (NASDAQ:NEXM)
Storico
Da Set 2023 a Set 2024